Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.98 USD | -0.97% | -3.66% | +14.39% |
May. 15 | Walgreens to Sell Over-the-Counter Naloxone Anti-Narcotic Spray to Reverse Opioid Overdoses | MT |
May. 09 | Truist Adjusts HCI Group's Price Target to $140 From $130, Keeps Buy Rating | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 363.4 | 417.5 | 856.3 | 346.7 | 851.1 | 1,047 | - |
Enterprise Value (EV) 1 | 363.4 | 417.5 | 856.3 | 346.7 | 851.1 | 1,047 | 1,047 |
P/E ratio | - | - | - | - | 11.5 x | 9.38 x | 9.12 x |
Yield | 3.5% | 3.06% | 1.92% | 4.04% | 1.83% | 1.6% | 1.63% |
Capitalization / Revenue | 1.5 x | 1.34 x | 2.1 x | 0.69 x | 1.55 x | 1.35 x | 1.32 x |
EV / Revenue | 1.5 x | 1.34 x | 2.1 x | 0.69 x | 1.55 x | 1.35 x | 1.32 x |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | 1.91 x | 2.02 x | 2.62 x | 2.09 x | 2.62 x | 2.11 x | 1.7 x |
Nbr of stocks (in thousands) | 7,961 | 7,982 | 10,251 | 8,757 | 9,738 | 10,476 | - |
Reference price 2 | 45.65 | 52.30 | 83.54 | 39.59 | 87.40 | 99.98 | 99.98 |
Announcement Date | 3/5/20 | 3/11/21 | 3/8/22 | 3/9/23 | 3/7/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 242.5 | 310.4 | 407.9 | 499.6 | 550.7 | 775.7 | 794 |
EBITDA | - | - | - | - | - | - | - |
EBIT | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 36.09 | 36.93 | 11.23 | -68.42 | 117.6 | 206.7 | 190.5 |
Net income 1 | 26.58 | 27.58 | 1.856 | -58.51 | 79.03 | 144.3 | 138.8 |
Net margin | 10.96% | 8.88% | 0.45% | -11.71% | 14.35% | 18.6% | 17.48% |
EPS 2 | - | - | - | - | 7.620 | 10.66 | 10.97 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | 1.600 | 1.600 | 1.600 | 1.600 | 1.600 | 1.600 | 1.627 |
Announcement Date | 3/5/20 | 3/11/21 | 3/8/22 | 3/9/23 | 3/7/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 112.3 | 127 | 125.9 | 126.7 | 119.9 | 129 | 127.3 | 131.6 | 162.7 | 206.6 | 199.1 | 187.6 | 183 | 193.2 | 199.6 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 2.538 | 4.001 | -11.56 | -63.6 | 2.743 | 23.14 | 20.27 | 20.09 | 54.16 | 77.43 | 59.47 | 22.79 | 47.66 | 53.82 | 53 |
Net income 1 | 0.028 | 0.903 | -9.981 | -50.96 | 1.526 | 15.34 | 12.44 | 13.16 | 38.1 | 47.61 | 43.46 | 16.18 | 34.69 | 39.59 | 39 |
Net margin | 0.02% | 0.71% | -7.93% | -40.23% | 1.27% | 11.89% | 9.77% | 9.99% | 23.42% | 23.04% | 21.83% | 8.63% | 18.95% | 20.49% | 19.54% |
EPS 2 | 0.0100 | - | - | - | - | 1.540 | 1.280 | 1.340 | 3.400 | 3.810 | 3.333 | 1.193 | 2.680 | 2.905 | 2.895 |
Dividend per Share 2 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | 0.4000 | - | 0.4000 | 0.4000 | 0.4000 | 0.4067 | 0.4067 |
Announcement Date | 3/8/22 | 5/4/22 | 8/8/22 | 11/8/22 | 3/9/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/7/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | 14.5% | 14.3% | 0.34% | -19.5% | 35.6% | 31% | 21.9% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | 23.90 | 25.80 | 31.90 | 18.90 | 33.40 | 47.30 | 59.00 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/5/20 | 3/11/21 | 3/8/22 | 3/9/23 | 3/7/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.39% | 1.05B | |
+39.42% | 62.15B | |
+18.91% | 53.45B | |
+21.10% | 44.74B | |
+35.98% | 37.77B | |
+12.64% | 30.09B | |
+50.87% | 28.45B | |
+26.88% | 25.7B | |
+2.32% | 22.11B | |
+17.14% | 21.63B |
- Stock Market
- Equities
- HCI Stock
- Financials HCI Group, Inc.